Abstract
The 5-HT1A receptor has been extensively studied over the last two decades. There is a plethora of information describing its anatomical, physiological and biochemical roles in the brain. In addition, the development of selective pharmacological tools coupled with our understanding of psychiatric pathology has lead to multiple hypotheses for the therapeutic utility of 5-HT1A agents and in particular 5-HT1A receptor antagonists. Over the last decade it has been suggested that 5-HT1A receptor antagonists may have therapeutic utility in such diseases as depression, anxiety, drug and nicotine withdrawal as well as schizophrenia. However, a very compelling rationale has been developed for the therapeutic potential of 5-HT1A receptor antagonists in Alzheimers disease and potentially other diseases with associated cognitive dysfunction. Receptor blockade by a 5-HT1A receptor antagonist appears to enhance activation and signaling through heterosynaptic neuronal circuits known to be involved in cognitive p rocesses and, as such, represents a novel therapeutic approach to the treatment of cognitive deficits associated with Alzheimers disease and potentially other disorders with underlying cognitive dysfunction.
Keywords: 5-HT1A Receptor Antagonists, Alzheimers Disease
Current Pharmaceutical Design
Title: The Potential Utility of 5-HT1A Receptor Antagonists in the Treatment of Cognitive Dysfunction Associated with Alzheimers Disease
Volume: 8 Issue: 2
Author(s): L. E. Schechter, L. A. Dawson and J. A. Harder
Affiliation:
Keywords: 5-HT1A Receptor Antagonists, Alzheimers Disease
Abstract: The 5-HT1A receptor has been extensively studied over the last two decades. There is a plethora of information describing its anatomical, physiological and biochemical roles in the brain. In addition, the development of selective pharmacological tools coupled with our understanding of psychiatric pathology has lead to multiple hypotheses for the therapeutic utility of 5-HT1A agents and in particular 5-HT1A receptor antagonists. Over the last decade it has been suggested that 5-HT1A receptor antagonists may have therapeutic utility in such diseases as depression, anxiety, drug and nicotine withdrawal as well as schizophrenia. However, a very compelling rationale has been developed for the therapeutic potential of 5-HT1A receptor antagonists in Alzheimers disease and potentially other diseases with associated cognitive dysfunction. Receptor blockade by a 5-HT1A receptor antagonist appears to enhance activation and signaling through heterosynaptic neuronal circuits known to be involved in cognitive p rocesses and, as such, represents a novel therapeutic approach to the treatment of cognitive deficits associated with Alzheimers disease and potentially other disorders with underlying cognitive dysfunction.
Export Options
About this article
Cite this article as:
Schechter E. L., Dawson A. L. and Harder A. J., The Potential Utility of 5-HT1A Receptor Antagonists in the Treatment of Cognitive Dysfunction Associated with Alzheimers Disease, Current Pharmaceutical Design 2002; 8 (2) . https://dx.doi.org/10.2174/1381612023396483
DOI https://dx.doi.org/10.2174/1381612023396483 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial: Generation Rx: Adolescent Prescription Drug Abuse
Current Drug Abuse Reviews Design, Synthesis and In Vitro Anti-microbial Evaluation of Ethylene/ Propylene-1H-1,2,3-Triazole-4-Methylene-tethered Isatin-coumarin Hybrids
Current Topics in Medicinal Chemistry Neuroimaging in Obsessive-Compulsive Disorder
Current Medical Imaging Targeting Tau Hyperphosphorylation <I>via</I> Kinase Inhibition: Strategy to Address Alzheimer's Disease
Current Topics in Medicinal Chemistry Opioids and Opioid Maintenance Therapies: Their Impact on Monocyte-Mediated HIV Neuropathogenesis
Current HIV Research Non-Analgesic Effects of Opioids: Cardiovascular Effects of Opioids and their Receptor Systems
Current Pharmaceutical Design Alzheimers Disease Related
Current Bioactive Compounds Molecular Imaging Strategies for In Vivo Tracking of MicroRNAs: A Comprehensive Review
Current Medicinal Chemistry Oral Immune Regulation: A New Mode of Therapy Against Chronic Viral Infections
Recent Patents on Anti-Infective Drug Discovery Green Supramolecular Solvent-Based Liquid-Phase Microextraction Method for Spectrophotometric Determination of Aluminum in Food, Water, Hair and Urine Samples
Current Analytical Chemistry MYC-Mediated Synthetic Lethality for Treating Tumors
Current Cancer Drug Targets Targeting miRNAs for Drug Discovery: A New Paradigm
Current Molecular Medicine Adherence to Antiretroviral Therapy and Tuberculosis Treatment in a Prison of Tehran, Iran
Infectious Disorders - Drug Targets Recent Applications of Nanomaterials Based on Electrochemical Drug Analysis
Current Analytical Chemistry Editorial: Current Strategies in Targeting Brain Disorders
CNS & Neurological Disorders - Drug Targets Orexins/Hypocretins: Pain Regulation and Cellular Actions
Current Pharmaceutical Design Synthesis and Structure-Activity Studies of Peptide-Acridine/Acridone Conjugates
Current Medicinal Chemistry Current Neuropharmacological Interventions in Autism: Potential Drug Targets from Pre-clinical and Clinical Findings
Current Psychopharmacology Other Drugs Acting on Nervous System Associated with QT-Interval Prolongation
Current Drug Safety Gender Disparities on Access to Care and Coronary Disease Management
Current Pharmaceutical Design